PolyActiva Commences Its First Phase I Clinical Trial with Potential to Improve Daily Lives of Millions of Glaucoma Patients
MELBOURNE, Australia--(BUSINESS WIRE)--Revolutionary new glaucoma treatment, which could remove need for eye drop use, enters clinical trials with USD$12m venture capital-backing.